Mavelertinib (formerly PF-06747775; PF06747775) is a mutant-selective, orally bioactive and irreversible/covalent inhibitor of the epidermal growth factor receptor (EGFR) T790M. It has potential antineoplastic activity. As as EGFR T790M inhibitor, PF-06747775 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance.

纯度：≥98%

CAS：1776112-90-3